Dr. Tagawa on Next Steps for Taxanes in Prostate Cancer

Scott T. Tagawa, MD
Published: Thursday, Mar 02, 2017



Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.

Although these results do not suggest changing from one particular taxane to the other, TAXYNERGY validated androgen receptor (AR) translocation as a mechanism of action of taxane chemotherapy, says Tagawa.

The next step is to use biomarkers to look at drug-target engagement in clinical trials, says Tagawa, which would hopefully determine the most effective AR plus a taxane combination for patients.
 


Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.

Although these results do not suggest changing from one particular taxane to the other, TAXYNERGY validated androgen receptor (AR) translocation as a mechanism of action of taxane chemotherapy, says Tagawa.

The next step is to use biomarkers to look at drug-target engagement in clinical trials, says Tagawa, which would hopefully determine the most effective AR plus a taxane combination for patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x